Zybro Clear-N Tablet is a combination pharmaceutical formulation containing Acebrophylline 100 mg and Acetylcysteine 600 mg, indicated for the management of respiratory conditions characterized by bronchial obstruction and excessive mucus production. Acebrophylline, a bronchodilator with mucolytic and anti-inflammatory properties, acts by relaxing bronchial smooth muscles and reducing airway inflammation, thereby improving airflow and easing breathing. Acetylcysteine, a potent mucolytic agent, facilitates the breakdown of disulfide bonds in mucus glycoproteins, leading to decreased mucus viscosity and enhanced clearance of secretions from the respiratory tract. This synergistic action makes Zybro Clear-N effective in the treatment of chronic obstructive pulmonary disease (COPD), bronchitis, asthma, and other respiratory disorders associated with thick, tenacious mucus and airway constriction. The tablet is typically administered orally, with dosage and duration tailored according to the severity of the condition and patient response. Caution is advised in patients with known hypersensitivity to either component, and monitoring is recommended for potential adverse effects such as gastrointestinal disturbances or allergic reactions. Zybro Clear-N should be used under medical supervision to ensure optimal therapeutic outcomes and to minimize risks.